Bradfordhill

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Triple-negative breast cancer2 trials
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 35 trials
• Phase 1/23 trials
• Phase 2/33 trials
• Phase 21 trial

Status

• Recruiting9 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Bristol-Myers Squibb10 trials
• Eli Lilly and Company1 trial
• Pfizer1 trial

Running trials

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0149

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0005

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0077

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0064

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0199

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0007

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Carlos Gallardo, Site 0018

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Carlos Rojas (principal investigator)

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0047

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

  Contact: Carlos Rojas, Site 0214

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer7 recruiting
• Triple-negative breast cancer2 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting